| Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. | |
| | |
MedLine Citation:
|
PMID: 15492765 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Nebivolol is a racemic mixture of d- and l-enantiomers. The drug is characterized by beta(1)-adrenoceptor selectivity and long-acting beta-blockade exerted predominantly by d-enantiomer. Nebivolol is devoid of intrinsic sympathomimetic activity and has no relevant membrane stabilizing action. Antiproliferative properties of nebivolol were demonstrated in endothelial and smooth muscle cell cultures. Infusion of nebivolol causes a vasodilation in all vascular beds by endothelial-dependent mechanism involving stimulation of beta(3)-adrenoceptors as well as by endothelial-independent mechanism. Nebivolol possesses not only direct vasodilator properties but also augments the action of endothelium-dependent vasodilators. The antioxidant property of nebivolol can at least in part explain why treatment with this drug enhances eNOS activity and minimizes the reperfusion-induced myocardial injury. The systemic effects of nebivolol in humans have an unusual hemodynamic profile. In contrast to traditional beta-adrenoceptor antagonists, nebivolol reduces preload and afterload due to systemic vasodilation and improves arterial distensibility. At 5 mg daily nebivolol effectively reduces systolic and diastolic blood pressure over a 24-h period. During treatment with nebivolol arterial pressure follows the natural circadian rhythm. Trough-to-peak ratio for nebivolol is 0.9. It has been demonstrated in numerous placebo-controlled studies that exercise tolerance is not reduced during nebivolol therapy. By chronic administration to patients with left ventricular dysfunction nebivolol increases myocardial contractility. Nebivolol produced no significant changes in lipid levels, insulin sensitivity or glucose tolerance. These findings make nebivolol a promising therapeutic tool for the treatment of arterial hypertension and chronic heart failure. |
| | |
Authors:
|
Alexey Kuroedov; Francesco Cosentino; Thomas F Lüscher |
Related Documents
:
|
10956355 - Beta-adrenergic blockade augments glucose utilization in horses during graded exercise. 6797085 - Exercise-induced bronchoconstriction as an expression of bronchial hyperreactivity: a s... 16903965 - Evaluation of exercise-induced t wave changes in patients with idiopathic dilated cardi... 2896635 - Effects of beta-blockade and exercise on cardiovascular and cognitive functioning. 17365045 - Serum dioxin levels in residents living in the vicinity of municipal waste incinerators... 16494595 - Exercise test mode dependency for ventilatory efficiency in women but not men. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Cardiovascular drug reviews Volume: 22 ISSN: 0897-5957 ISO Abbreviation: Cardiovasc Drug Rev Publication Date: 2004 |
Date Detail:
|
Created Date: 2004-10-19 Completed Date: 2005-02-22 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9006912 Medline TA: Cardiovasc Drug Rev Country: United States |
Other Details:
|
Languages: eng Pagination: 155-68 Citation Subset: IM |
Affiliation:
|
Cardiovascular Research, Institute of Physiology, University of Zurich-Irchel, CH-8057 Zurich, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
administration & dosage,
adverse effects,
pharmacology* Angina Pectoris / drug therapy Animals Benzopyrans / administration & dosage, adverse effects, pharmacology* Endothelium, Vascular / drug effects, physiopathology Ethanolamines / administration & dosage, adverse effects, pharmacology* Heart Failure / drug therapy Humans Hypertension / drug therapy Muscle, Smooth, Vascular / drug effects, physiopathology Myocardial Reperfusion Injury / drug therapy Receptors, Adrenergic, beta-1 / antagonists & inhibitors*, metabolism Vasodilator Agents / administration & dosage, adverse effects, pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Benzopyrans; 0/Ethanolamines; 0/Receptors, Adrenergic, beta-1; 0/Vasodilator Agents; 99200-09-6/nebivolol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.
Next Document: Cardiovascular protective effects of resveratrol.